Abstract
We present here a novel semi-synthetic cyclic ether fluorinated noscapine analog (CEFNA) that shows potent antiproliferative and anticancer activity in both hormone-responsive (MCF-7) and hormone non-responsive (MDA-MB-231) breast cancer cells. Interestingly, it is also effective against MCF-7/Adr, an adriamycin-resistant variant of MCF-7 cells. Immunofluorescence experiments showed numerous micronuclei, indicative of apoptotic cell death triggered by this novel analog. Mechanistically, CEFNA exerts a strong antimitotic effect as revealed by cell-cycle studies that show a dose-dependent increase in G2/M population preceding a rising sub-G1 population, suggesting apoptosis.
Publication types
-
Evaluation Study
-
Research Support, N.I.H., Extramural
MeSH terms
-
Antibiotics, Antineoplastic / adverse effects
-
Antitussive Agents / chemical synthesis*
-
Antitussive Agents / chemistry
-
Antitussive Agents / pharmacology*
-
Apoptosis / drug effects
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / pathology
-
Cell Cycle / drug effects
-
Doxorubicin / adverse effects
-
Drug Resistance, Neoplasm
-
Flow Cytometry
-
Fluorescent Antibody Technique
-
Humans
-
Noscapine / chemical synthesis*
-
Noscapine / chemistry
-
Noscapine / pharmacology*
-
Spindle Apparatus / drug effects
-
Tumor Cells, Cultured / drug effects
Substances
-
Antibiotics, Antineoplastic
-
Antitussive Agents
-
Doxorubicin
-
Noscapine